Abstract
Graves’ disease is an autoimmune disorder characterized by a course of remission and relapse. Several parameters have been evaluated for their abilities to predict the clinical course of Graves’ disease in patients treated with antithyroid drugs. We recently demonstrated in patients with hyperthyroidism dependent by Graves’ disease, an impaired Na+, K+ ATPase activity in red cells and a correlation between ATPase and free T3. With the aim to clarify the relationship between the course of hyperthyroidism and the Na+, K+ ATPase activity during and after discontinuing the antithyroid therapy, we followed up 24 patients for two years. In our previous work by restoring a normal level of free T3, we obtained a normalization of Na+, K+ ATPase activity in the red cells of all the patients. However, in eigth subjects after a period of 150 days following the suspension of therapy, we observed a new reduction of ATPase activity in a clinical condition of euthyroidism. The same subjects, newly evaluated after 150 days, developed a clinical and biochemical relapse of hyperthyroidism. We believe that the determination of Na+ K+ ATPase activity is able to predict the recurrence of hyperthyroidism in patients with Graves’ disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Reinwien D., Benker G., Lazarus J.H., Alexander W.D. and The European Multicenter Study Group on Antithyroid Drug Treatment. A prospective randomized trial of antithyroid drug dose in Graves’ disease therapy. J. Clin. Endocrinol. Metab. 76: 1516, 1993.
Winsa B., Dahlberg P.A., Jansson R., Agren H., Karlsson F.A. Factors influencing the outcome of thyrostatic drug theraphy in Graves’ disease. Acta Endocrinol. (Copehn.) 122: 722, 1990.
Solomon B., Glinoer D, Lagasse R., Wartofsky L. Current trends in the managment of Graves’ disease. J. Clin. Endocrinol. Metab. 70: 1519, 1990.
Allanic H., Fauchet R., Lorcy Y., Gueguen M., Le Guerrier A.M., Genetet B. A perspective study on the relationship between relapse of hyperthyroidism Graves’ disease after antithyroid drugs and HLA aplotype. J. Clin. Endocrinol. Metab. 57: 719, 1983.
Takamatsu J., Kuma K., Mozai T. Serum triiodothyronine to tyroxine ratio:a newly recognized predictor of the outcome of hyperthyroidism due to Graves’ disease. J. Clin. Endocrinol. Metab. 62: 980, 1985.
Dahlberg P.A., Karlsson F.A., Jansson R., Wide L. Thyrotropin-realising hormone testing during antithyroid drug treatment of Graves’ disease as an indicator of remission. J. Clin. Endocrinol. Metab. 61: 1100, 1985.
Ikenoue H., Okamura K., Sato K., Kuroda T., Lyoshinari M., Itokuyama T., Nakakawa M., Fujishima M. Prediction of relapse in drug treated Graves’ disease using thyroid stimulation indices. Acta Endocrinol. (Copehn.) 125: 643, 1991.
Feldt-Rasmussen U., Scheleusener H., Carayon P. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves’ disease. J. Clin. Endocrinol. Metab. 78: 98, 1994.
Vitti P., Rago T., Mancusi F., Pallini S., Tonacchera M., Santini F., Chiovato L., Marcocci C., Pinchera A. Thyroid hypoechogenic pattern at ultrasonography as a tool for predicting the recurrence of hyperthyroidism after medical treatment in patients with Graves’l disease. Acta Endocrinol. (Copehn.) 126: 128, 1992.
Notsu K., Oka N., Masaki Y., Furuya H., Kato Y. Plasma free triiodothyronine response to thyrotropinrealising hormone predict the remission of Graves disease treated with antithyroid drugs. J. Clin. Endocrinol. Metab. 73: 396, 1990.
De Riva C., Su Chen, Virgili F., Frigato F. Na+K+ATPase activity and ouabain binding sites in erythrocytes in hyperthyroidism before and after therapy. J. Endocrinol. Invest. 15: 363, 1992.
Daly J.A., Ertinghausen G. Direct method for the determination inorganic phosphate in serum with Centrifichem. Clin. Chem 18: 263, 1972.
Rubython E.J., Cumbertach M., Morgan D.B. Changes in the number and activity of sodium pump from patients with hyperthyroidism. Clin. Sci. 64: 441, 1983.
Skou Jc. The Na-K pump. Methods Enzymol. 156: 1, 1988.
Faramarz I.B. Thyroid Hormone regulation of Na,K-ATPase expression. Trends Endocrinol. Metab. 4: 152, 1993.
Gefland R., Hutchinson-Willams K., Bonde A., Castellino P., Sherwin R. Catabolic effects of thyroid hormones excess: the contribution of adrenergic activity to hypermetabolism and protein breakdown. Metab. Clin. Exp. 26: 562, 1987.
Wolman S., Sheppard H., Fern M. The effect of triiodothyronine (T3) on protein turnover and metabolic rate. Int. J. Obesity 9: 459, 1985.
Valdemarsson S., Ikomikumm J., Monti M. Increased lymphocyte thermogenesis in hyperthyroid patients-Role of Na/K pump function. Acta Endocrinol. (Copehn.) 126: 291, 1992.
Winsa B., Adami H-O., Bergstrom R., Gamstedt A., Dahlberg P.A., Adamson U., Jansson R., Karlsson A. Stressful life events and Graves’ disease. Lancet 338: 1475, 1991.
Lagaye S., Vexiau P., Morozov V., Guenebaut-Laudet V., Tobay-Tapiero J., Canivet M., Cathelinau G., Peries J., Emanoil-Ravier R. Human spumaretrovirus-related sequences in the DNA of leukocytes from patients with Graves’ disease. Proc. Natl. Acad. Sci. 89:10070,1992.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
De Riva, C., Virgili, F. Na+, K+ ATPase activity in red cells predicts the recurrence of hyperthyroidism in patients with Graves’ disease. J Endocrinol Invest 18, 683–689 (1995). https://doi.org/10.1007/BF03349789
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03349789